Neurocrine price target raised to $170 from $164 at Guggenheim

Guggenheim raised the firm’s price target on Neurocrine to $170 from $164 and keeps a Buy rating on the shares. Ingrezza sales came in slightly ahead of the firm’s and consensus estimates, showing sequential growth from Q4 to Q1 for the third consecutive year, notes the analyst, who argues that Neurocrine’s “solid quarter and rich pipeline rightfully motivate the growing positive sentiment on the stock.”